Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger B Cohen

Showing results (61-70 of 208) with videos related to

Pageof 21
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancersNancy L Lewis, Lionel D Lewis, Joseph P Eder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?Kevin P Weinfurt, Damon M Seils, Li Lin, et al.
Clinical Lung Cancer|January 30, 2022
Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of ImmunotherapyMelina E Marmarelis, Yu-Xiao Yang, Wei-Ting Hwang, et al.
BMC Cancer|March 8, 2017
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumorsPatricia M LoRusso, Jeffrey R Infante, Kevin B Kim, et al.
JAMA Oncology|November 4, 2021
Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid CancersRavi B Parikh, Eun Jeong Min, E Paul Wileyto, et al.
Investigational New Drugs|April 21, 2017
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumorsJeffrey R Infante, Roger B Cohen, Kevin B Kim, et al.
Investigational New Drugs|July 6, 2017
Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumorsJeffrey R Infante, Roger B Cohen, Kevin B Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2009
Effects of food on the relative bioavailability of lapatinib in cancer patientsKevin M Koch, Nandi J Reddy, Roger B Cohen, et al.
JAMA Otolaryngology-- Head & Neck Surgery|August 18, 2022
Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint InhibitorsSara B Hobday, Robert M Brody, Barry Kriegsman, et al.
American Journal of Clinical Oncology|April 22, 2016
Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non-Small Cell Lung Cancer Receiving Sequential TreatmentGenevieve Maquilan, Surbhi Grover, Eric Xanthopoulos, et al.
Pageof 21

Showing results (61-70 of 208) with videos related to

Sort By:
Pageof 21
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2009
Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868,596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancersNancy L Lewis, Lionel D Lewis, Joseph P Eder, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 24, 2012
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question?Kevin P Weinfurt, Damon M Seils, Li Lin, et al.
Clinical Lung Cancer|January 30, 2022
Platinum Re-Exposure as a Non-Small Cell Lung Cancer (NSCLC) Treatment Strategy in the Age of ImmunotherapyMelina E Marmarelis, Yu-Xiao Yang, Wei-Ting Hwang, et al.
BMC Cancer|March 8, 2017
A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumorsPatricia M LoRusso, Jeffrey R Infante, Kevin B Kim, et al.
JAMA Oncology|November 4, 2021
Uptake and Survival Outcomes Following Immune Checkpoint Inhibitor Therapy Among Trial-Ineligible Patients With Advanced Solid CancersRavi B Parikh, Eun Jeong Min, E Paul Wileyto, et al.
Investigational New Drugs|April 21, 2017
A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumorsJeffrey R Infante, Roger B Cohen, Kevin B Kim, et al.
Investigational New Drugs|July 6, 2017
Erratum to: A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumorsJeffrey R Infante, Roger B Cohen, Kevin B Kim, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2009
Effects of food on the relative bioavailability of lapatinib in cancer patientsKevin M Koch, Nandi J Reddy, Roger B Cohen, et al.
JAMA Otolaryngology-- Head & Neck Surgery|August 18, 2022
Outcomes Among Patients With Mucosal Head and Neck Squamous Cell Carcinoma Treated With Checkpoint InhibitorsSara B Hobday, Robert M Brody, Barry Kriegsman, et al.
American Journal of Clinical Oncology|April 22, 2016
Analysis of the Relationship Between Response to Chemotherapy and Response to Radiation Therapy in Patients With Non-Small Cell Lung Cancer Receiving Sequential TreatmentGenevieve Maquilan, Surbhi Grover, Eric Xanthopoulos, et al.
Pageof 21